ArticleAnnals of clinical and translational neurology2023
Plasma phosphorylated tau181 predicts cognitive and functional decline.
Article in Annals of clinical and translational neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 27 citations in OpenAlex.
- Blood-based multiplex nanobiosensing of Alzheimer's disease biomarkers: from nanoengineered ınterfaces to clinical translation.Metabolic brain disease · 2026Review
- Loss of neuronal population organization links pathology to behavior in a model of Alzheimer's disease.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Review
- Plasma p-tau217 best captures early longitudinal cognitive changes in subjective cognitive decline compared with p-tau181 and NfL.Journal of neurology · 2026Article
- Multi-domain AD risk burden and plasma biomarkers in cognitively unimpaired adults.medRxiv : the preprint server for health sciences · 2026Article
- Association between Plasma P-tau217 and Alzheimer's Copathology and Cognitive Decline in Parkinson's Disease.Annals of neurology · 2026Observational
- Loss of neuronal population organization links pathology to behavior in a model of Alzheimer's disease.bioRxiv : the preprint server for biology · 2026Article
- Clinical validation of new alzheimer disease diagnosis tools based on plasma p-Tau217.Scientific reports · 2025Article
- Plasma p-tau181 as a Marker of Conversion to Alzheimer's Disease Dementia and Worsening in Cognitive Functions in Subjective Cognitive Decline and Mild Cognitive Impairment: A Longitudinal Study.Annals of clinical and translational neurology · 2025Article
- Plasma proteomic associations with Alzheimer's disease endophenotypes.Nature aging · 2025Article
- Distinctive volumetric associations between plasma p-tau181 and hippocampal formation structures across the Alzheimer's disease continuum.Journal of Alzheimer's disease : JAD · 2025Article
- Synergistic Autophagy-Related Mechanisms of Protection Against Brain Aging and AD: Cellular Pathways and Therapeutic Strategies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Electrochemical Technology for the Detection of Tau Proteins as a Biomarker of Alzheimer's Disease in Blood.Biosensors · 2025Review
- Association of plasma biomarkers of Alzheimer's pathology and neurodegeneration with gait performance in older adults.Communications medicine · 2025Article
- ADNI Biomarker Core: A review of progress since 2004 and future challenges.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Blood biomarkers as surrogate endpoints in Alzheimer's disease research.Frontiers in aging neuroscience · 2025Article
- Alzheimer's disease biomarkers and their current use in clinical research and practice.Molecular psychiatry · 2025Review
- Pathologic and cognitive correlates of plasma biomarkers in neurodegenerative disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Medial temporal lobe gray matter microstructure in preclinical Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Comparison of plasma biomarkers and amyloid PET for predicting memory decline in cognitively unimpaired individuals.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo determine if plasma tau phosphorylated at threonine 181 (p-tau181) distinguishes pathology-confirmed Alzheimer's disease (AD) from normal cognition (NC) adults, to test if p-tau181 predicts cognitive and functional decline, and to validate findings in an external cohort.
methodsThirty-one neuropathology-confirmed AD cases, participants with clinical diagnoses of mild cognitive impairment (MCI, N = 91) or AD dementia (N = 64), and NC (N = 241) had plasma collected at study entry. The clinical diagnosis groups had annual cognitive (Mini-Mental State Examination, MMSE) and functional (Clinical Dementia Rating Scale, CDR) measures. NC (N = 70), MCI (N = 75), and AD dementia (N = 50) cases from the Alzheimer's Disease Neuroimaging Initiative (ADNI) were used as a validation cohort. Plasma p-tau181 was measured using the Quanterix SiMoA HD-X platform.
resultsPlasma p-tau181 differentiated pathology-confirmed AD from NC with negative amyloid PET scans with an AUC of 0.93. A cut point of 3.44 pg/mL (maximum Youden Index) had a sensitivity of 0.77, specificity of 0.96. p-Tau181 values above the cut point were associated with the faster rate of decline in MMSE in AD dementia and MCI and a shorter time to a clinically significant functional decline in all groups. In a subset of MCI cases from ADNI, p-tau181 values above the cut point associated with faster rate of decline in MMSE, and a shorter time to a clinically significant functional decline and conversion to dementia.
interpretationPlasma p-tau181 differentiates AD pathology cases from NC with high accuracy. Higher levels of plasma p-tau181 are associated with faster cognitive and functional decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.